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httpcense.Abstract Background: Pneumonia is a common illness in all parts of the world. It is a major cause
of death among all age groups and is the leading cause of death in children in low income countries.
Methods: This prospective study was done at Department of chest diseases and microbiology
from January 2011 to July 2011. A total of 60 patients, with pneumonia were included in the study.
Results: The present study was conducted on 60 patients with pneumonia who have been admit-
ted to the Chest Department in the Main University Hospital in Alexandria (55 patients) and El
Maamoura Chest Hospital (5 patients) in the period from January 2011 to April 2011. The patients
were subdivided into 2 groups: group I includes 30 patients with CAP and group II includes 30
patients with HAP; 16 patients with COPD, 7 patients with bronchial asthma, 4 patients with bron-
chogenic carcinoma and 3 patients with ILF.
Conclusions: We can conclude that, Chlamydophila pneumoniae cannot be ignored as a cause of
pneumonia. ELISA is an excellent screening test because of its high sensitivity for detection of C.
pneumoniae while PCR is more accurate because of its high sensitivity and high speciﬁcity in diag-
nosis of C. pneumoniae infection.DM is a risk factor for C. pneumoniae infection.
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Pneumonia can be generally deﬁned as inﬂammation of the
lung parenchyma, and is characterized by consolidation of
the affected part and a ﬁlling of the alveolar air spaces with
exudate, inﬂammatory cells and ﬁbrin [1].
Pneumonia is a common illness in all parts of the world. It
is a major cause of death among all age groups and is the lead-
ing cause of death in children in low income countries [2]. In
children, many of these deaths occur in the newborn period.is. Production and hosting by Elsevier B.V.
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newborn infant deaths are due to pneumonia [3].
Over two million children under ﬁve die each year world-
wide and it is estimated that up to 1 million of these (vaccine
preventable) deaths are caused by the bacteria Streptococcus
pneumoniae and over 90% of these deaths take place in devel-
oping countries. Mortality from pneumonia generally de-
creases with age until late adulthood with increased
mortality in the elderly [4].
More cases of pneumonia occur during the winter months
than during other times of the year. Pneumonia occurs more
commonly in males than females, and more often in blacks than
caucasians due to differences in synthesizing vitamin D from
sunlight. Individuals with underlying illnesses such as Alzhei-
mer’s disease, cystic ﬁbrosis, emphysema, tobacco smoking,
alcoholism, or immune system problems are at increased risk
for pneumonia. These individuals are alsomore likely to have re-
peated episodes of pneumonia. People who are hospitalized for
any reason are also at high risk for pneumonia [5].
Atypical bacteria are generally associated with a milder
form of pneumonia, the so-called ‘‘walking pneumonia.’’ A
feature that makes these organisms atypical is the inability to
detect them on Gram stain or to cultivate them in standard
bacteriologic media as the following atypical organisms:
Mycoplasma pneumoniae, Chlamydophila species (C. psittaci,
C. pneumoniae), Legionella species and Coxiellaburnetii [6,7].
Chlamydophila pneumoniae is a species ofChlamydophila bac-
teria that infects humans and is amajor cause of pneumonia [8,9].
The ﬁrst known case of infection with C. pneumoniae was a
case of sinusitis in Taiwan. This atypical bacterium commonly
causes pharyngitis, bronchitis and atypical pneumonia [10].
Numerous serological studies have conﬁrmed that C. pneu-
moniae is a cause of community acquired pneumonia through-
out the world. It is estimated tocause 10%–20% of
community-acquired pneumonia cases among adults. In most
instances, the diagnosis has been based on a signiﬁcant in-
crease in speciﬁc IgG titers.
As chlamydiae are intracellular bacteria, they cannot be
grown by conventional techniques. C. trachomatis was ﬁrst
grown in chick embryos in 1957 and in HeLa 229 cell cultures
in 1971 [11]. Initially, C. pneumoniae grew poorly in these prep-
arations but techniques such as centrifugation of the organism
onto cell culture monolayers [12] and other reﬁnements as re-
gards the culture medium have improved results [13].
Nevertheless, culture of C. pneumoniae is not a widely avail-
able technique and certain clinical samples such as sputum are
toxic towards cell cultures. Whereas C. pneumoniae infection
diagnosis has often been by non-culture techniques with the
consequence that results are sometimes open to different inter-
pretation, so it is better for implication of cell culture in the
diagnosis [14].
The methods used to measure C. pneumoniae-speciﬁc anti-
bodies vary from laboratory to laboratory, and there is a need
for the improvement, simpliﬁcation and standardization of the
methods to be used [15].
According to the CDC, microimmunoﬂuorescence (MIF) is
the serological method of choice for the diagnosis of acute C.
pneumoniae infection, but it requires time, is difﬁcult to per-
form and must be subjectively interpreted by an expert opera-
tor with a ﬂuorescence microscope [16].
ELISAs were developed to overcome the shortcomings of
MIF. Thus, they require less time, are more objective (photo-metric reading of results) and are easier to standardize because
results are expressed in international units [17].
Polymerase chain reaction
Numerous molecular ampliﬁcation techniques based on geno-
mic sequences have been applied to detect and differentiate
Chlamydophila species, including DNA hybridization with
genomic DNA probes, polymorphic analysis of restriction
fragments of PCR-ampliﬁed products and nested PCR, among
others. These techniques have shown a higher sensitivity in
comparison to culture and other diagnostic tests for the detec-
tion of Chlamydophila infection in certain tissues and respira-
tory samples [18].Aim of the work
Our study aimed to evaluate the prevalence of C. pneumoniae
in patients suffering from pneumonia in the Main University
hospital in Alexandria using PCR ampliﬁcation and ELISA
technique.
Subjects
I. This study was conducted on 60 patients who
have been admitted to the Chest department in
the Alexandria Main University hospital (55
patients) and from El Maamoura Chest Hospital
(5 patients). These patients were subdivided into
two groups:
Group 1: thirty patients with community acquired pneu-
monia (CAP);
Group 2: thirty patients with hospital acquired pneumonia
(HAP);
Ten sex and age matched healthy individuals have been en-
rolled in the study as a control group.
Informed consents have been taken from all cases and con-
trol group enrolled in this study.
I. Studied cases were subjected to:
1. Detailed history taking e.g. personal history (e.g. age,
sex) and previous medical diseases.
2. Complete physical examination and pulmonary scoring;
including blood pressure, respiratory rate and heart rate.
3. Plain X-ray Chest in a Postero-anterior (PA) view.
4. The WBCs count.
5. Sputum samples collection for DNA extraction and
PCR ampliﬁcation.
6. Serum samples taking from all cases and from control
group for detection of C. pneumoniae IgM via ELISA.
Methods
Laboratory assay
I. C. pneumoniae DNA detection in sputum sample
1–3 ml of morning sputum expectorated deep from the lung
have been collected into wide mouthed sterile plastic cups,
Figure 2 The line gene K detector system.
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20 C to be used for PCR ampliﬁcation.
DNA extraction and ampliﬁcation have been performed
using C. Pneumoniae Fluorescent Polymerase Chain Reaction
Diagnostic Kit (see Fig. 1).
Following the manufacturer’s instructions, the sputum
samples have been taken and physiological saline solutions
have been added in volume of four times, then shaken gently
and put in the refrigerator at 4 C overnight to make sputum
liqueﬁed completely. This mixture has been mixed well with
tip or pipette, then 1 ml have been taken to 1.5 ml centrifuge
tube and centrifuged at 12,000 rpm for 5 min. The supernatant
has been removed, 50 ll of DNA extraction buffer have been
added to the sediment and mixed them completely. The mix-
ture has been incubated at 100 C (constant temperature) for
10minutes then centrifugation was performed at 12,000 rpm
for 5 min then kept at 20 C for later ampliﬁcation.
Negative and positive controls have been processed accord-
ing to the manufacturer’s instructions.
Real-time PCR was performed with the Line gene K detec-
tor system (Fig. 2). The gene coding for the major outer mem-
brane protein (MOMP) was used as the target for
ampliﬁcation using probe (50-FAM-TCC CCT TGC CAA
CAG ACG CTG G-TAMRA-30); and a pair of primers: for-
ward primer (50-AAG GGC TAT AAA GGC GTT GCT-30)
and reverse primer (50-TGG TCG CAG ACT TTG TTC
CA-30).
Following the manufacturer’s instructions, PCR reaction
solution and Taq mixture have been taken in the proportion
of PCR reaction solution 40 ll/test and Taq mixture 3 ll/
tested then mixed well (43 ll/test), loaded into 0.2 ml PCR
reaction tubes and reserved for sampling.
Two microliters of the sample supernatants prepared above
have been respectively added including specimen, negative
control, low positive control, and high positive control as total
reaction volume in each test tube was 45 ll. Centrifugation was
performed at 8,000 rpm for a few seconds, and thetubes have
been placed in theinstrument and sampled well. Selecting re-
porter dye as FAM and quencher dye as TAMRA was per-
formed (Table 1).Figure 1 C. pneumoniae ﬂuorescent polymerase chain reaction
diagnostic kit.To setup PCR reaction condition under the ‘‘Instrument’’
heading and to setup steps of ﬂuorescence detection the follow-
ing steps have been done (Table 2).
Recording the value of the unknown specimen (C) in the
Report heading was performed. C represents the content of
sample and Ct is cycle threshold.
– If there was obvious ampliﬁcation curve or Ct value <30
and total content of CP DNA in the sample was more than
the detection limit, the results were positive.
– If there was no ampliﬁcation curve or Ct value P30 and
total content of CP DNA in the sample was less than the
detection limit, the results were negative.
II. C. pneumoniae IgM detection in serum samples
Blood samples have been taken from both groups; patients and
controls, left to coagulate then centrifuged for serum separa-
tion and stored in refrigerator at 2–8 C for later performance
of quantitative detection of IgM antibodies speciﬁed for C.
pneumoniae (Fig. 3).
According to the manufacturer’s instructions, patient sam-
ples and also control samples have been diluted in dilution buf-
fer as a concentration 1:100 and reagents of the ELISA assay
have been prepared.
Reading within 60 min at 405 nm against substrate blank
was performed using ELISA reader (Fig. 4).
Calculation SERION ELISA classic C. pneumoniae IgM
For the test evaluation a standard curve and an evaluation ta-
ble were included in the test kit. The reference value and the
validity range of the standard serum were given on the evalu-
ation table.Table 1 Steps of PCR ampliﬁcation.
Number of cycles Temperature Time (min)
Denaturation 1 93 C 2:00
Annealing 10 Step 1: 93 C 0:45
Step 2: 55 C 1:00
Extension 30 Step 1: 93 C 0:30
Step 2: 55 C 0:45
Table 2 The sex and the age in the studied cases.
Pneumonia Test of signiﬁcance
HAP CAP Total
Sex Male No (%) 16 (53.3%) 25 (83.3%) 41 (68.3%) X= 6.239
Female No (%) 14 (46.7%) 5 (16.7%) 19 (31.7%) P= 0.012**
Age <30 years No (%) 0 (0.0%) 2 (6.7%) 2 (3.3%) X= 17.676
30–60 years No (%) 8 (26.7%) 22 (73.3%) 30 (50.0%) P= 0.000**
1 >60 years No (%) 22 (73.3%) 6 (20.0%) 28 (46.7%)
P level of signiﬁcance, signiﬁcance <0.05.
Chi-square test.
** Signiﬁcant.
Figure 3 SERION ELISA classic C. pneumoniae IgM.
364 S.M. Sadaka et al.Substrate blank has been subtracted from all OD-values
prior to the evaluation. The following methods were
performed:
Method I: Qualitative evaluation
For ﬁxing the cut-off ranges, multiplying the mean value of the
measured standard-OD with the numerical data of the certiﬁ-
cate of quality control was performed e.g.
Upper cut-off = 0.502 · the mean value of the measured
standard-OD.
Lower cut-off = 0.352 · the mean value of the measured
standard-OD.Figure 4 ELISA reader.Cut-off value is the mean of upper and lower cut-off.
If OD value of patient’s sample > cut-off value, the result
was positive.
If OD value of patient’s sample < cut-off value, the result
was negative.
Method II: Quantitative evaluation
Continuous determination of antibody activities using the
standard curve were compensated by multiplication of the cur-
rent measured value obtained with a patient’s sample with the
correction factor F.
1. This factor was calculated as following:
2. The mean of the two OD-values of the standard serum had
to be calculated and checked that it was within the given
validity range.
3. Calculation of the factor (F): the given reference value was
divided by the mean of the extinction of the standard
serum:
F ¼ Reference value of standard serum
Current value of standard serums
4. All measured values of patient’s samples were multiplied by
(F).
5. Antibody activities in IU/ml or U/ml were determined from
the standard curve with the corrected values.
Positive result: >15 U/ml.
Borderline result: 10–15 U/ml.
Negative result: <10 U/ml.
Methods of statistical analysis
After data entry into a specially designed sheet using Microsoft
Excel, a print out of the data was thoroughly revised and data
entry mistakes were corrected, then the ﬁle was transferred into
Statistical Package for Social Science (SPSS) version 17 format
and data explore was carried out. Comparison of distribution
for the categorical variable was performed using cross tabula-
tion with Chi square test or any of the corrected Chi square as
indicated. Alpha error was set to 5% instead.
Results
The present study was conducted on 60 patients with pneumo-
nia who have been admitted to the Chest Department in the
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Maamoura Chest Hospital (5 patients) in the period from Jan-
uary 2011 to April 2011. The patients were subdivided into 2
groups: group I includes 30 patients with CAP and group II in-
cludes 30 patients with HAP; 16 patients with COPD, 7 pa-
tients with bronchial asthma, 4 patients with bronchogenic
carcinoma and 3 patients with ILF (Tables 3–9).
Correlation between PCR and ELISA results in the studied
cases
Table 10 and Fig. 5 show that all the 3 PCR positive cases were
ELISA positive while among the 5 ELISA positive cases, 3
were PCR positive with IgM concentration of 24, 20 and
17 U/ml. It is noticeable that high concentration of IgM were
in patients with PCR positive for C. pneumoniae as shown in
Fig. 12. It is evident that ELISA is a good screening test for
detection of C. pneumoniae infection and PCR is more speciﬁc
and accurate in detection of C. pneumoniae infection in pa-
tients with pneumonia (X= 34.737,P= .000).
Correlation between personal history and different PCR results
for C. pneumoniae in the studied cases
Table 11 shows that all the 3 cases PCR positive were males, 2
of them were ranged between 30–60 years old while only 1 was
above 60 years old, 2 of them were from urban areas whileTable 3 Geographic distribution and smoking in the studied cases.
Pneumo
HAP
Residence Urban No (%) 27 (90.0
Rural No (%) 3 (10.0%
Smoking Non-smoker No (%) 16 (53.3
Smoker No (%) 14 (46.7
P level of signiﬁcance, signiﬁcance <0.05.
Chi-square test.
* Insigniﬁcant.
** Signiﬁcant.
Table 4 The state of the lung in the studied cases.
Pneumonia on healthy lung (No = 15)
Pneumonia on diseased lung (No = 45) Bronchial asthma (No = 21)
Lung cancer (No = 5)
COPD (No = 16)
ILF (No = 3)
P level of signiﬁcance, signiﬁcance <0.05.
Chi-square test.
* Insigniﬁcant.
** Signiﬁcant.only 1 was from rural areas, 2 of them were smokers while only
1 was non-smoker.
Correlation between the state of the lung and different PCR
results for C. pneumoniae in the studied cases
As shown in Table 12, all 3 positive PCR cases were on dis-
eased lung; 2 cases had bronchial asthma while 1 had lung
cancer.
Correlation between some medical diseases other than
pulmonary diseases and different PCR results for C. pneumoniae
in the studied cases
Table 13 shows that all the 3 PCR positive cases were diabet-
ics. It is evident that C. pneumoniae infection is signiﬁcantly
higher in the diabetic patients (X= 4.130,P= .042) while
only 1 case out of 3 PCR positive cases was hypertensive
(i.e. one patient suffer from DM and hypertension.Correlation between the use of mechanical ventilator and
different PCR results for C. pneumoniae in the studied cases
Table 14 shows that two cases out of 3 PCR positive cases were
on mechanical ventilator while only 1 case was not on mechan-
ical ventilator.nia Test of signiﬁcance
CAP Total
%) 25 (83.3%) 52 (86.7%) X= .577
) 5 (16.7%) 8 (13.3%) P= 0.448*
%) 6 (20.0%) 22 (36.7%) X= 7.177
%) 24 (80.0%) 38 (63.3%) P= 0.007**
Pneumonia Test of signiﬁcance
HAP CAP Total
No (%) 0 .0% 15 (50.0%) 15 (25.0%) X= 38.133
P= 0.000**
No (%) 7 (23.3%) 14 (46.7%) 21 (35.0%) X= 3.590
P= 0.058*
No (%) 4 (13.3%) 1 (3.3%) 5 (8.3%) X= 1.964
P= 0.161*
No (%) 16 (53.3%) 0 (0.0%) 16 (26.7%) X= 21.818
P= 0.000**
No (%) 3 (10.0%) 0 (0.0%) 3 (5.0%) X= 3.158
P= 0.076*
Table 5 Some medical diseases other than pulmonary diseases in the studied cases.
Pneumonia Test of signiﬁcance
HAP CAP Total
DM Negative No (%) 13 (43.3%) 21 (70.0%) 34 (56.7%) X= 4.344
Positive No (%) 17 (56.7%) 9 (30.0%) 26 (43.3%) P= 0.037**
Hyper-tension Negative No (%) 1 (3.3%) 17 (56.7%) 18 (30.0%) X= 20.317
Positive No (%) 29 (96.7%) 13 (43.3%) 42 (70.0%) P= 0.000**
P level of signiﬁcance, signiﬁcance <0.05.
Chi-square test.
** Signiﬁcant.
Table 6 The use of mechanical ventilator in the studied cases.
Pneumonia Test of signiﬁcance
HAP CAP Total
Patients on mechanical ventilator Negative No (%) 1 (3.3%) 27 (90.0%) 28 (46.7%) X= 45.268
Positive No (%) 29(96.7%) 3 (10.0%) 32 (53.3%) P= 0.000**
** Statistically signiﬁcant.
Table 7 Symptoms and Signs in the studied cases.
Pneumonia Test of signiﬁcance
HAP CAP Total
Sputum appearance Mucoid No (%) 7 (23.3%) 16 (53.3%) 23 (38.3%) X= 6.38
Muco-purulent No (%) 17 (56.7%) 12 (40.0%) 29 (48.3%) P= 0.041**
Bloody No (%) 6 (20.0%) 2 (6.7%) 8 (13.3%) X= 17.067
Fever Persistent No (%) 23 (76.6%) 7 (23.3%) 30 (50.0%) P= 0.000**
Intermittent No (%) 7 (23.3%) 23(76.63) 30 (50.0%)
Dyspnea Degree I No (%) 0 (.0%) 11 (36.7%) 11 (18.3%)
Degree II No (%) 1 (3.3%) 15 (50.0%) 16 (26.7%) X= 43.450
Degree III No (%) 16 (53.3%) 4 (13.3%) 20 (33.3%) P= 0.000**
Degree IV No (%) 13 (43.3%) 0 (.0%) 13 (21.7%)
** Statistically signiﬁcant.
Table 8 Prevalence of C. pneumoniae by PCR and ELISA tests in the studied cases.
Pneumonia Test of signiﬁcance
HAP CAP Total
PCR Negative No (%) 29 (96.7%) 28 (93.3%) 57 (95.0%) X= 0.351
Positive No (%) 1 (3.3%) 2 (6.7%) 3 (5.0%) P= 0.554*
ELISA Negative No (%) 28 (93.3%) 27 (90.0%) 55 (91.7%) X= 0.218
Positive No (%) 2 (6.7%) 3 (10.0%) 5 (8.3%) P= 0.640*
* Statistically signiﬁcant.
Table 9 Laboratory and radiological ﬁndings in the studied cases.
Pneumonia Test of signiﬁcance
HAP CAP Total
WBC count <11,000 cells/cmm No (%) 2 (6.7%) 4 (13.3%) 6 (10.0%) X= 0.741
>11,000 cells/cmm No (%) 28 (93.3%) 26 (86.7%) 54 (90.0%) P= 0.389*
Atchy consolidation on Chest X-rays Of one lung No (%) 20 (66.7%) 24 (80.0%) 44 (73.3%) X= 1.364
Of both lungs No (%) 10 (33.3%) 6 (20.0%) 16 (26.7%) P= 0.243*
* Statistically signiﬁcant.
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Table 10 Correlation between PCR and ELISA results in the studied cases.
PCR Test of signiﬁcance
Negative (No = 57) Positive (No = 3) Total (No = 60)
ELISA Negative (No = 55) No (%) 55 (96.5%) 0 (0.0%) 55 (91.7%) X= 34.737
Positive (No = 5) No (%) 2 (3.5%) 3 (100.0%) 5 (8.3%) P= 0.000**
** Statistically signiﬁcant.
Figure 5 Case No. IgM concentration in PCR and ELISA
positive cases. +ve ELISA Cut-off value = 0.10; +ve PCR
Mean value of the measured standard-OD= 0.239; ve PCR
Reference value = 26.3 U/ml; F factor = 110 U/ml.
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results for C. pneumoniae in the studied cases
Table 15 shows that 2 cases out of 3 PCR positive cases were
with mucoid sputum while only 1 case was with bloody spu-
tum, 2 cases out of 3 PCR positive cases were with intermittent
fever while 1 case was with persistent fever. As regard degree of
dyspnea; 1 case with dyspnea degree II, 1 case with dyspnea de-
gree III and 1 case with dyspnea degree IV.
Correlation between laboratory and radiological ﬁndings and
different PCR results for C. pneumoniae in the studied cases
Table 15 shows that all 3 PCR positive cases were with leuco-
cytosis (WBC counts more than 11.000 cells/cmm) and ChestTable 11 Correlation between personal history and different PCR
PCR
Negative (No = 57)
Gender Male No (%) 38 (66.7%)
Female No (%) 19 (33.3%)
Age <30 years No (%) 2 (3.5%)
30–60 years No (%) 28 (49.1%)
>60 years No (%) 27 (47.4%)
Residence Urban No (%) 50 (87.7%)
Rural No (%) 7 (12.3%)
Smoking Non-Smoker No (%) 21 (36.8%)
Smoker No (%) 36 (63.2%)
* Statistically signiﬁcant.X-ray showed that 2 cases out of 3 PCR positive cases were
with patchy consolidation of one lung while one case was with
patchy consolidation of both lungs.Discussion
C. pneumoniae is an intracellular pathogen that causes acute
infections of the respiratory tract, provokes immune dysfunc-
tion and leads to chronic inﬂammation. Infections with C.
pneumoniae show high rates of recurrence since the memory di-
rected to this pathogen is temporary and only partial [19].
Yet, currently available information usually does not allow
differentiation between recurrences due to re-infections and
those resulting from chronic persistent infection. There is evi-
dence supporting that these organisms indeed can persist for
extended periods in human host cells, however, factors that
lead to persistence of C. pneumoniae are only partly under-
stood [20].
In a trial to estimate the possible role of C. pneumoniae in
provocation of infection in our pneumonic patients; we con-
ducted our study on 60 pneumonic patients (30 patients with
HAP, 30 patients with CAP) using PCR ampliﬁcation and
ELISA technique.
Our study was in line with other studies conducted in var-
ious parts of the world; with some differences between the dif-
ferent studies as follows:
In our study, Real-time PCR of sputum samples revealed
only 3 patients out of 60 cases (5%) were infected with C. pneu-
moniae during their infection but as regard ELISA of serum
samples; revealed that 5 patients out of 60 cases (8.3%) had
positive ELISA results for C. pneumoniae.
This was in agreement with study of Gaydos et al. con-
ducted a prospective study in Maryland on 385 patients who
had community-acquired pneumonia with use of a modiﬁed
polymerase chain reaction assay that detects ampliﬁed DNA
by enzyme immunoassay (EIA). C. pneumoniae was detectedresults for C. pneumoniae in the studied cases.
Test of signiﬁcance
Positive (No = 3) Total (No = 60)
3 (100.0%) 41(68.3%) X= 1.463
0 (0.0%) 19 (31.7%) P= 0.226*
0 (.0%) 2 (3.3%) X= 0.401
2 (66.7%) 30 (50.0%) P= 0.818*
1 (33.3%) 28 (46.7%)
2 (66.7%) 52 (86.7%) X= 1.093
1 (33.3%) 8 (13.3%) P= 0.296*
1 (33.3%) 22 (36.7%) X= 0.015
2 (66.7%) 38 (63.3%) P= 0.902*
Table 12 Correlation between the state of the lung and different PCR results for C. pneumoniae in the studied cases.
PCR Test of
signiﬁcance
Negative (No = 57) Positive (No = 3) Total (No = 60)
Pneumonia on healthy
lung (No = 15)
No (%) 15 (26.3%) 0 (0.0%) 15 (25.0%) X= 5.063
P= 0.281*
Pneumonia on diseased
lung (No = 45)
Bronchial asthma No (%) 19 (33.3%) 2 (66.7%) 21 (35.0%) X= 1.392
P= 0.238*
Lung cancer No (%) 4 (7.0%) 1 (33.3%) 5 (8.3%) X= 2.584
P= 0.108*
COPD No (%) 16 (28.1%) 0 (0.0%) 16 (26.7%) X= 1.148
P= 0.284*
ILF No (%) 3 (5.3%) 0 (.0%) 3 (5.0%) X= 0.166
P= 0.684*
* Statistically signiﬁcant.
Table 13 Correlation between some medical diseases other than pulmonary diseases and different PCR results for C. pneumoniae in
the studied cases.
PCR Test of signiﬁcance
Negative (No = 57) Positive (No = 3) Total (No = 60)
DM Negative No (%) 34 (59.6%) 0 (0.0%) 34 (56.7%) X= 4.130
Positive No (%) 23 (40.4%) 3(100.0%) 26 (43.3%) P= 0.042**
Hypertension Negative No (%) 16 (28.1%) 2 (66.7%) 18 (30.0%) X= 2.022
Positive No (%) 41 (71.9%) 1 (33.3%) 42 (70.0%) P= 0.155*
* Statistically signiﬁcant.
Table 14 Correlation between the use of mechanical ventilator and different PCR results for C. pneumoniae in the studied cases.
PCR Test of signiﬁcance
Negative (No = 57) Positive (No = 3) Total (No = 60)
Patients on mechanical ventilator Negative No (%) 27 (47.4%) 1 (33.3%) 28 (46.7%) X= 0.226
Positive No (%) 30 (52.6%) 2 (66.7%) 32 (53.3%) P= 0.635*
* Statistically signiﬁcant.
Table 15 Correlation between laboratory and radiological ﬁndings and different PCR results for C. pneumoniae in the studied cases.
PCR Test of signiﬁcance
Negative
(No = 57)
Positive
(No = 3)
Total
(No = 60)
WBC count <11,000 cells/cmm No (%) 6 (10.5%) 0 (0.0%) 6 (10.0%) X= 0.351
>11,000 cells/cmm No (%) 51 (89.5%) 3 (100%) 54 (90.0%) P= 0.554*
Patchy consolidation on Chest X-ray One lung No (%) 42 (73.7%) 2 (66.7%) 44 (73.3%) X= 0.072
Two lungs No (%) 15 (26.3%) 1 (33.3%) 16 (26.7%) P= 0.789*
* Statistically signiﬁcant.
368 S.M. Sadaka et al.by PCR-EIA in only thirteen (3.4%) of these 385 patients. In
addition, in 46 (11.9%) out of the 385 patients had titers of
antibody that PCR-EIA was more sensitive than was culture
for detecting C. pneumoniae infection in this study, this method
may be a valuable tool for the prompt diagnosis of this infec-
tion [21].
In contrast to our study, Nagalingam et al. investigated the
prevalence of current C. pneumoniae infections in patients with
pneumonia in Trinidad from 126 patients diagnosed by attend-
ing physicians, as suffering from pneumonia at four hospitals
in Trinidad. Serum samples were tested for C. pneumoniaeIgM by the enzyme immunoassay (EIA) and also both IgM
and IgG were detected using microimmunoﬂuorescence
(MIF). Seroprevalences of 46.0% (58 of 126) were found for
C. pneumoniae IgM/G. It was concluded that new infections
by C. pneumoniae in pneumonia patients may be an important
etiological agent for the condition in Trinidad [22].
Also, Choi et al. clariﬁed the endemic status of C. pneumo-
niae in Seoul, Korea by collection serum samples from 98 pa-
tients with acute pneumonia who visited Hanyang University
Hospital in Korea, from January 1996 to November 1997 for
C. pneumoniae antibody measurement by MIF test. The
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centage of recent infection with C. pneumoniae was 12 cases
(12%) for those with IgG antibodies and 6 cases (6%) for
those with IgM antibodies. Choi et al. suggested that the prev-
alence of C. pneumoniae is associated with population density,
which may explain the higher rate of positivity in Seoul, a city
with a high population density [23].
The results of these studies added to our own results show
the importance of C. pneumoniae in provocation of infection in
our pneumonic patients.
In our study, we chose a wide age-range and when we clas-
siﬁed patients into 3 groups (below 30, between 30 and 60 and
above 60 years), we found that C. pneumoniae infection is more
prevalent in the middle age groups between 30–60 years
(66.7%). As regard the gender; we collected 41 male patients
and 19 female patients with pneumonia and we found that
all PCR positive cases are males (100%).
This was in accordance with a study done in Iceland to
examine the prevalence of C. pneumoniae. The study was based
on 1020 serum samples from individuals 0–99 years old. The
samples were divided into 10-year age groups. IgG and IgM
antibodies were determined with microimmunoﬂuorescence as-
say. It was lowest in the youngest group, 0–9 years old, but
rose linearly to age 70. Thirty-four samples were IgM positive;
most from the older age groups. It was concluded that the
prevalence of C. pneumoniae infections is high in Iceland and
similar to that in neighboring countries [24].
Similarly, serum specimens from 223 patients with acute
lower respiratory tract infection in Germany were examined
for antibodies to C. pneumoniae using the microimmunoﬂuo-
rescence test. Antibodies to C. pneumoniae were detected in
18 (20%) out of 91 children and 64 (48%) out of 132 adults.
Among those individuals, 4 (4%) children and 15 (11%) adults
had elevated IgG antibody titres indicating acute or recent
infection. Speciﬁc IgM antibodies were observed in two pa-
tients. These results suggest that a signiﬁcant proportion of
lower respiratory tract infections in Germany is caused by C.
pneumoniae [25].
In our study, we found that C. pneumoniae infection was
more prevalent among patients from urban areas more than
those from rural areas (66.7%).
This was similar with a study in Hungary investigated C.
pneumoniae antibodies in paired sera of 120 patients with var-
ious respiratory diseases. The study showed that the prevalence
of IgG antibody in children from the rural areas of Hungary
was about 50% lower than in children in the capital. The high
prevalence of persistent IgG, indicating earlier infection, sug-
gests that C. pneumoniae infection may be endemic in Budapest
[26].
In our study, we found that all PCR positive cases were dia-
betics (3 out of 26 diabetics patients) (11.5%) hence, DM may
be an important risk factor for C. pneumoniae infection.
Similarly, Mu¨ller et al. in Denmark evaluated the preva-
lence of C. pneumoniae DNA in the white cells of the periphe-
ral blood in 194 patients with diabetes mellitus, 50 patients
with acute coronary syndrome, 102 hypertensive patients,
193 patients having suffered a stroke and in 368 healthy sub-
jects with a nested polymerase chain reaction (nPCR). Overall
the prevalence of C. pneumoniaeDNA in peripheral blood cells
was: diabetes mellitus (11.9%), stroke (10.4%), hypertension
(6.9%), acute coronary syndrome (4.0%) and healthy subjects
(7.9%) [27].Also, in Japan although the role of C. pneumoniae infection
in diabetic patients is still not clear, the development of athero-
sclerotic plaques in diabetic patients may be accelerated by the
presence of C. pneumoniae in blood. Moreover, the develop-
ment of diabetes is likely to cause a compromised host-permit-
ting exceptional infection by immune suppression [28,29] and
such presence of escapable condition from host-defense system
probably could preserve C. pneumoniae survival and growth in
either lung or peripheral blood cells for a long-term. Thus, the
development of diabetes might be a possible factor for promot-
ing C. pneumoniae systemic dissemination [30].
In our study, we found that all 3 PCR positive cases (100%)
were with leucocytosis and Chest X-rays showed that 66.7% of
them were with patchy consolidation of 1 lung while 33.3%
were with patchy consolidation of both lungs.
This was in accordance with a prospective study in Thai-
land, between October 2000 and December 2002 that was con-
ducted among hospitalized community acquired pneumonia
(CAP) patients admitted to Srinagarind Hospital, KhonKaen,
Thailand. The prevalence of C. pneumoniae among patients
hospitalized with CAP was 8.7%; 24 cases out of 276 hospital-
ized CAP patients. Leucocytosis was found in 62.5% of pa-
tients. Localized patchy alveolar inﬁltration was the most
common radiographic ﬁnding, followed by bilateral interstitial
inﬁltration [31].
In our study, we found that all of PCR positive cases
(100%) were with productive cough (66.7% with mucoid spu-
tum and 33.3% with bloody sputum) and all of them (100%)
with dyspnea. As regard the state of the lung in our study,
all PCR positive cases (100%) were with pneumonia on dis-
eased lung (66.7% of them were with bronchial asthma while
33.3% were with lung cancer).
However, a Prospective studying Japan that was conducted
on forty patients with community-acquired pneumonia with C.
pneumoniae admitted to Kawasaki Medical School Hospital
between April 1996 and March 2001 to investigate their clini-
cal presentations. The following results have been obtained,
67.5% of the cases were with productive cough, 7.5% were
with Hemoptysis, 25% were with dyspnea. As regard the state
of lung in the studied cases, 10% were with COPD, 7.5% were
with bronchial asthma, 7.5% were with bronchogenic carci-
noma and 45% were with no underlying disease [32].
In our study, we found that the patients whose were PCR
positive for C. pneumoniae infection and had bronchial asthma
(66.7%) there was higher severity of asthma attacks in these
asthmatic patients, that explain that C. pneumoniae may be
an important precipitating factor for exacerbations of asthma.
In a study done on asthmatics of different grades of sever-
ity, a strong association was found between elevated antibody
levels to C. pneumoniae and the patients with moderate-to-se-
vere asthma. On the contrary, no signiﬁcant association was
found between elevated antibody levels and mild asthma, sug-
gesting that C. pneumoniae may be involved in the ampliﬁca-
tion of the inﬂammatory process in asthmatics, rather than
being an initiator of asthma [33].
Also, another study conducted by Cunningham et al. in
1998; found that more frequent attacks of asthma were associ-
ated with high antibody response to C. pneumoniae [34].
These results together with our own results; imply that C.
pneumoniae may be an important factor for exacerbations of
asthma whereas in chronic asthma, re-infection or persistent
infection may be associated with more severe disease.
370 S.M. Sadaka et al.From the current study results as well as results revealed
from similar studies in different countries, we conﬁrm the po-
tential role of C. pneumoniae in both hospital and community
acquired pneumonia.
From our results we can conclude that:
C. pneumoniae cannot be ignored as a cause of pneumonia.
ELISA is an excellent screening test because of its high sen-
sitivity for detection of C. pneumoniae while PCR is more
accurate because of its high sensitivity and high speciﬁcity
in diagnosis of C. pneumoniae infection.
DM is a risk factor for C. pneumoniae infection.
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